| __timestamp | MorphoSys AG | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 9689000 | 612613000000 |
| Thursday, January 1, 2015 | 10431000 | 650773000000 |
| Friday, January 1, 2016 | 9618000 | 619061000000 |
| Sunday, January 1, 2017 | 12348000 | 628106000000 |
| Monday, January 1, 2018 | 28310241 | 717599000000 |
| Tuesday, January 1, 2019 | 59336147 | 964737000000 |
| Wednesday, January 1, 2020 | 159145941 | 875663000000 |
| Friday, January 1, 2021 | 199800000 | 886361000000 |
| Saturday, January 1, 2022 | 90225000 | 997309000000 |
| Sunday, January 1, 2023 | 92538000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Takeda Pharmaceutical Company Limited, a leader in the global market, and MorphoSys AG, a prominent player in biotechnology, offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Takeda's SG&A expenses have shown a steady upward trajectory, peaking at over 1 trillion yen in 2023, reflecting a strategic expansion and increased operational costs. In contrast, MorphoSys AG's SG&A expenses, while significantly lower, have experienced a dramatic rise, increasing by over 900% from 2014 to 2021, before stabilizing.
This divergence highlights Takeda's robust market presence and MorphoSys's aggressive growth strategy. The absence of data for MorphoSys in 2024 suggests a potential shift or reevaluation in their financial reporting or strategy.
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Sarepta Therapeutics, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and MorphoSys AG
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
MorphoSys AG and Evotec SE: SG&A Spending Patterns Compared